Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.
1. A method of evolution of a template human protein in a manufacturing host, the method comprising:
a. mutating the template human protein to produce a set of mutant human proteins in the manufacturing host;
b. screening the set of mutant progeny proteins for at least one predetermined property, characteristic or activity;
c. selecting an up-mutant human protein from the set of mutant human proteins based upon the at least one predetermined property, characteristic or activity; and
d. manufacturing the up-mutant human protein comprising expressing the up-mutant human protein in the same production host as in the mutating step (a).
2. The method of claim 1 , wherein the manufacturing host is selected the group consisting of 3T3 mouse fibroblast cells; BHK21 Syrian hamster fibroblast cells; MDCK, dog epithelial cells; Hela human epithelial cells; PtK1 rat kangaroo epithelial cells; SP2/0 mouse plasma cells; and NSO mouse plasma cells; HEK 293 human embryonic kidney cells; COS monkey kidney cells; CHO, CHO-S Chinese hamster ovary cells; R1 mouse embryonic cells; E14.1 mouse embryonic cells; H1 human embryonic cells; H9 human embryonic cells; PER C.6, human embryonic cells; S. cerevisiae yeast cells; and pichia yeast cells.
3. The method of claim 2 , wherein the manufacturing host is CHO-S or HEK293.
4. The method of claim 1 , wherein the mutating step (a) comprises generating n-1 separate sets of mutant human proteins from the template human protein, each set comprising member mutant human protein having X number of different predetermined amino acid residues at a single predetermined position of the template human protein; wherein each set of mutant human proteins differs in the single predetermined position; and the number of different member mutant human proteins generated is equivalent to [n−1]×X.
5. The method of claim 1 , wherein 1 wherein X is 19.
6. The method of claim 1 , wherein the predetermined property, characteristic or activity is selected from reduction of protein-protein aggregation, enhancement of protein stability, increased protein solubility, introduction of glycosylation sites, introduction of conjugation sites, reduction of immunogenicity, enhancement of protein expression, increase in antigen affinity, decrease in antigen affinity, change in binding affinity, change in immunogenicity, and enhancement of specificity.
7. The method of claim 1 , wherein the template human protein is selected by:
a1. generating a human protein library in a cell production host selected from one of the group consisting of a bacterial or eukaryotic production host;
a2. screening the library for the at least one predetermined property, characteristic or activity; and
a3. selecting the template human protein from the library based upon the at least one predetermined property, characteristic or activity, the selecting step (c) comprises:
selecting the up-mutant human protein from the set of mutant human proteins based upon (1) optimization of the at least one predetermined property, characteristic or activity and (2) modified expression when compared to the template human protein.
8. The method of claim 7 , wherein the modified expression is improved expression.
9. The method of claim 1 , wherein the mutating step (a) comprises one of comprehensive positional evolution (CPE); comprehensive positional insertion evolution (CPI); comprehensive positional deletion evolution (CPD); comprehensive positional evolution (CPE) followed by combinatorial protein synthesis (CPS); or comprehensive positional deletion evolution (CPD) followed by combinatorial protein synthesis (CPS).
10. The method of claim 1 , wherein the human protein is an antibody.
11. The method of claim 10 , wherein the antibody is a full length antibody.
12. The method of claim 1 , wherein the at least one predetermined property, characteristic or activity in screening step (b) comprises one or more of (1) screening for a silent mutation and (2) screening for a missense mutation; compared to the template human protein.
13. The method of claim 1 , wherein the template human protein is selected from an enzyme, a cytokine, a receptor, a DNA binding protein, a chelating agent, and a hormone.
14. The method of claim 1 , wherein the manufacturing host is a eukaryotic production host and the mutating step (a) comprises evolving the template human protein to produce a set of mutant human proteins in the eukaryotic cell production host with cell surface display.
15. The method of claim 1 , wherein the template human protein is an approved ethical protein therapeutic drug, and the up-mutant human protein is a biosimilar.
16. The method of claim 1 , wherein the selecting step (c) further comprises
selecting an up-mutant human protein from the set of mutant human proteins based upon (1) optimization of the at least one predetermined property, characteristic or activity when compared to the template human protein, and (2) modified expression when compared to the template human protein.
17. The method of claim 16 , wherein the modified expression is enhanced expression.
18. The method of claim 1 , wherein the screening step (b) comprises:
screening the set of mutant human proteins for at least one predetermined property, characteristic or activity and screening for enhanced expression when compared to the template human protein; and
the selecting step (c) comprises:
selecting an up-mutant human protein from the set of mutant human proteins based upon (1) retention or optimization of the at least one predetermined property, characteristic or activity and (2) enhanced expression when compared to the template human protein.
19. The method of claim 18 wherein the screening step (b) comprises screening the set of mutant human proteins for the at least one predetermined property, characteristic or activity and screening for enhanced expression simultaneously.
20. The method of claim 7 , wherein the cell production host in step (a1) is same as the manufacturing host in steps (a) and (d).